American Association of Individual Investors

Why Atossa Therapeutics, Inc.’s (ATOS) Stock Is Down 9.72%

As of Wednesday, December 31, Atossa Therapeutics, Inc.’s ATOS share price has dipped by 9.72%, which has investors ...
Veri Apriyatno Drawings on MSN

Powerful realistic drawing showcasing Atossa Shahbanu’s grace

Royal dignity and composed strength define this realism drawing inspired by Atossa Shahbanu, a princess remembered for ...

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...
Morningstar

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval SEATTLE, Dec. 11, 2025 /PRNewswire/ -- ...
Yahoo Finance

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven conditions SEATTLE, Dec. 9, 2025 ...
The Globe and Mail

Atossa Completes FDA Meeting on Regulatory Strategies

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Finanznachrichten

Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities, including a Type C meeting ...
Seeking Alpha

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reduction SEATTLE, Dec. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ...
KXAN

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

SEATTLE, Dec. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other ...
Investing

FDA grants rare pediatric disease designation for Atossa’s DMD drug

SEATTLE - The U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to Atossa Therapeutics’ (NASDAQ:ATOS) (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy, the ...
Investing

Ascendiant Capital raises Atossa Genetics stock price target to $8 from $7.75

Atossa also announced the potential of (Z)-endoxifen in addressing Duchenne Muscular Dystrophy, highlighting its pharmacological benefits for multiple disease drivers. In preparation for potential ...